Ftse Mib
34.640,43
0,88%
DAX
18.763,81
0,45%
S&P 500
5.223,75
0,19%
NASDAQ
16.336,00
-0,06%
Bitcoin
61.753,06
-2,05%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Nkarta Inc (NKTX) Nkarta Inc (NKTX) Notizie

Nkarta Inc

NKTX
6,24
-0,06 (-0,95%)
Ultimo aggiornamento: 16:29:54
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
09/5/202422:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:04EDGAR2Form 8-K - Current report
09/5/202422:01GLOBENkarta Reports First Quarter 2024 Financial Results and..
03/4/202422:02GLOBENkarta to Participate in Upcoming Investor Conferences
25/3/202411:30GLOBENkarta Announces Pricing of $240 Million Underwritten..
21/3/202421:01GLOBENkarta Reports Fourth Quarter and Full Year 2023 Financial..
05/3/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202422:32EDGAR2Form 144 - Report of proposed sale of securities
28/2/202414:01GLOBENkarta to Participate in Upcoming Investor Conferences
15/2/202403:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:20EDGAR2Form 144 - Report of proposed sale of securities
09/2/202412:38EDGAR2Form SC 13D/A - General statement of acquisition of..
18/1/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202422:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202422:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202422:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202422:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202414:50EDGAR2Form 8-K - Current report
03/1/202422:15EDGAR2Form S-8 - Securities to be offered to employees in employee..
10/12/202302:31GLOBENkarta Presents NKX101 Clinical Data at the 2023 American..
13/11/202314:25EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/11/202322:19EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:06EDGAR2Form 8-K - Current report
09/11/202322:02GLOBENkarta Reports Third Quarter 2023 Financial Results and..
07/11/202314:02GLOBENkarta to Participate at Upcoming Investor Conferences
27/10/202322:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
17/10/202318:00DJNNkarta's Stock Climbs 28% After FDA Approves Drug..
17/10/202317:47PRNUSLupus Therapeutics Announces Partnership to Support the..
17/10/202313:06EDGAR2Form 8-K - Current report
17/10/202313:01GLOBENkarta Receives FDA Clearance of IND Application for NKX019..
16/10/202322:07EDGAR2Form 8-K - Current report
16/10/202322:01GLOBENkarta to Host Conference Call on Tuesday, October 17 at 8am..
23/8/202322:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202313:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202313:05EDGAR2Form 8-K - Current report
10/8/202313:01GLOBENkarta Reports Second Quarter 2023 Financial Results and..
03/8/202314:02GLOBENkarta to Participate at Upcoming Investor Conference
05/7/202322:09EDGAR2Form 8-K - Current report
05/7/202322:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202322:02GLOBENkarta Appoints Alyssa Levin Chief Financial and Business..
27/6/202313:01GLOBENkarta Updates Clinical Progress of CAR-NK Cell Therapy..
26/6/202322:01GLOBENkarta to Host Conference Call to Discuss Updated Clinical..
10/6/202316:47GLOBENkarta Presents NKX019 Clinical Data at the European..
11/5/202322:02GLOBENkarta Reports First Quarter 2023 Financial Results and..
11/5/202322:01GLOBENkarta to Present NKX019 Phase 1 Dose Escalation Data at..
Apertura: 6,50 Min: 6,03 Max: 6,50
Chiusura: 6,30

La tua Cronologia

NASDAQ
NKTX
Nkarta
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network